Marina E Cazzaniga

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8022104/publications.pdf

Version: 2024-02-01

78 papers	3,984 citations	172457 29 h-index	118850 62 g-index
79 all docs	79 docs citations	79 times ranked	4792 citing authors

#	Article	IF	Citations
1	The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients. Anti-Cancer Drugs, 2022, 33, e628-e634.	1.4	4
2	Abstract OT2-19-06: Phase 2 study of abemaciclib in combination with endocrine therapy with or without paclitaxel induction in patients with hormone receptor-positive, HER2-negative advanced breast cancer and aggressive disease criteria: ABIGAIL. Cancer Research, 2022, 82, OT2-19-06-OT2-19-06.	0.9	0
3	How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story. Life, 2022, 12, 378.	2.4	8
4	Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. Journal of Clinical Oncology, 2022, 40, 3246-3256.	1.6	190
5	Methotrexate inhibits SARSâ€CoVâ€2 virus replication â€œin vitroâ€. Journal of Medical Virology, 2021, 93, 1780-1785.	5.0	38
6	Managing Menopausal Symptoms in Young Women With Breast Cancer: When Medicine Is Not All. The Take Care Project. Clinical Breast Cancer, 2021, 21, e547-e560.	2.4	3
7	The Role for Tocilizumab in COVID-19 Patients: Reflections on Monza Cohort Data. Infection and Drug Resistance, 2021, Volume 14, 1389-1392.	2.7	0
8	Metronomic Chemotherapy. Cancers, 2021, 13, 2236.	3.7	38
9	Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9). Breast Cancer Research and Treatment, 2021, 190, 103-109.	2.5	3
10	Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study. Breast Cancer Research and Treatment, 2021, 190, 415-424.	2.5	6
11	Is There Still a Role for Endocrine Therapy Alone in HR+/HER2â€“ Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. Breast Care, 2020, 15, 30-37.	1.4	0
12	Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study. Breast, 2019, 48, 7-16.	2.2	37
13	Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future? . OncoTargets and Therapy, 2019, Volume 12, 2989-2997.	2.0	23
14	Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success. Breast Cancer Research and Treatment, 2019, 176, 483-494.	2.5	28
15	Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project. Advances in Therapy, 2019, 36, 381-406.	2.9	19
16	Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumoursâ€”the MACBETH project. Cancer Chemotherapy and Pharmacology, 2019, 83, 301-318.	2.3	1
17	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 474-485.	10.7	59
18	Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve. Supportive Care in Cancer, 2018, 26, 3143-3151.	2.2	23

#	Article	IF	Citations
19	Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine: what is the opinion of Italian oncologists?. Expert Review of Anticancer Therapy, 2018, 18, 805-814.	2.4	1
20	Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study. Oncotarget, 2018, 9, 27448-27459.	1.8	20
21	In reply to Kadri Altundag. Breast Cancer Research and Treatment, 2017, 161, 387-387.	2.5	0
22	Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting. Oncologist, 2017, 22, 648-654.	3.7	10
23	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. European Journal of Cancer, 2017, 82, 237-246.	2.8	38
24	Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience. Breast Cancer Research and Treatment, 2017, 163, 587-594.	2.5	9
25	Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials. Clinical Breast Cancer, 2017, 17, 433-440.	2.4	6
26	Metronomic chemotherapy for advanced breast cancer patients. Cancer Letters, 2017, 400, 252-258.	7.2	29
27	Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2â˜) advanced breast cancer patients: New insights beyond clinical trials. The EVA study. Breast, 2017, 35, 115-121.	2.2	21
28	Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20). Quality of Life Research, 2017, 26, 2999-3010.	3.1	51
29	Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?. International Journal of Breast Cancer, 2017, 2017, 1-6.	1.2	12
30	Efficacy and Safety of Vinorelbine-Capecitabine Oral Metronomic Combination in Elderly Metastatic Breast Cancer Patients: VICTOR-1 Study. Tumori, 2017, 103, e4-e8.	1.1	17
31	Is metronomic vinorelbine (mVRL) able to inhibit both HUVEC and triple-negative breast cancer (TNBC) cells? The proof-of-concept VICTOR-0 study.. Journal of Clinical Oncology, 2017, 35, e14014-e14014.	1.6	1
32	Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study. Breast Cancer Research and Treatment, 2016, 160, 501-509.	2.5	49
33	Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study. Journal of Cancer Research and Clinical Oncology, 2016, 142, 669-678.	2.5	14
34	Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development. Future Oncology, 2016, 12, 373-387.	2.4	43
35	Genetic determinants of chronic oxaliplatinâ€induced peripheral neurotoxicity: a genomeâ€wide study replication and metaâ€analysis. Journal of the Peripheral Nervous System, 2015, 20, 15-23.	3.1	34
36	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncology, The, 2015, 16, 1306-1315.	10.7	835

#	Article	IF	Citations
37	Everolimus-based therapy in patients with hormone receptor-positive, HER2- advanced breast cancer: management considerations. Future Oncology, 2015, 11, 2251-2254.	2.4	1
38	Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. Pharmacogenomics, 2014, 15, 1985-1999.	1.3	16
39	Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. Annals of Oncology, 2014, 25, 1373-1378.	1.2	84
40	Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study. International Journal of Breast Cancer, 2014, 2014, 1-7.	1.2	42
41	Longâ€term course of oxaliplatinâ€induced polyneuropathy: a prospective 2â€year followâ€up study. Journal of the Peripheral Nervous System, 2014, 19, 299-306.	3.1	67
42	Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 392-398.	1.9	116
43	Clinical pattern and associations of oxaliplatin acute neurotoxicity. Cancer, 2013, 119, 438-444.	4.1	179
44	Gene expression profiling in breast cancer: A clinical perspective. Breast, 2013, 22, 109-120.	2.2	73
45	Voltageâ€gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatinâ€induced peripheral neurotoxicity: Results from a prospective multicenter study. Cancer, 2013, 119, 3570-3577.	4.1	86
46	Advanced age and liability to oxaliplatinâ€induced peripheral neuropathy: <scp>post hoc</scp> analysis of a prospective study. European Journal of Neurology, 2013, 20, 788-794.	3.3	30
47	Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers. Tumori, 2013, 99, 596-600.	1.1	2
48	Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Annals of Oncology, 2012, 23, 3116-3122.	1.2	69
49	Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. Cancer Chemotherapy and Pharmacology, 2012, 70, 899-902.	2.3	37
50	Biological Characteristics and Medical Treatment of Breast Cancer in Young Womenâ€”A Featured Population: Results from the NORA Study. International Journal of Breast Cancer, 2011, 2011, 1-6.	1.2	27
51	Isotretinoin Plus Clindamycin Seem Highly Effective Against Severe Erlotinib-Induced Skin Rash in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 1662-1663.	1.1	22
52	Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study. Annals of Oncology, 2009, 20, 655-659.	1.2	18
53	Targeted Therapies for the Treatment of Breast Cancer in the Post-trastuzumab Era. Oncologist, 2008, 13, 373-381.	3.7	26
54	The anthracyclines and the clinical practice: do all breast cancer patients benefit? Results from the NORA study. Annals of Oncology, 2008, 19, 1811-1812.	1.2	0

#	Article	IF	Citations
55	From the trastuzumab era to new target therapies: beyond revolution. Annals of Oncology, 2007, 18, vi1-vi4.	1.2	8
56	Adjuvant treatment of early breast cancer: do the St Gallen recommendations influence clinical practice? Results from the NORA study. Annals of Oncology, 2007, 18, 1976-1980.	1.2	9
57	Breast cancer in elderly women: a different reality? Results from the NORA study. Annals of Oncology, 2007, 18, 991-996.	1.2	51
58	Diagnosis, Management and Clinical Outcome of Bone Metastases in Breast Cancer Patients: Results from a Prospective, Multicenter Study. Oncology, 2006, 71, 374-381.	1.9	14
59	Bisphosphonates and metastatic bone disease. Annals of Oncology, 2006, 17, ii91-ii95.	1.2	9
60	Adjuvant systemic treatment of early breast cancer: the NORA study. Annals of Oncology, 2006, 17, 1386-1392.	1.2	14
61	The extension of disease is associated to an increased risk of venous thromboembolism (VTE) in patients with gastrointestinal (GI) carcinoma. Thrombosis and Haemostasis, 2006, 95, 752-754.	3.4	7
62	Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study. Supportive Care in Cancer, 2005, 13, 375-380.	2.2	18
63	Acute dyspnea due to right phrenic palsy during infusional chemotherapy. Annals of Oncology, 2004, 15, 691-692.	1.2	0
64	Patterns of Relapse and Modalities of Treatment of Breast Cancer: The â€˜IRISâ€™ Project, a Multicenter Observational Study. Oncology, 2004, 66, 260-268.	1.9	8
65	Gilbert's syndrome and fluorouracil toxicity in colorectal cancer patients: which correlation?. Colorectal Disease, 2004, 6, 129-130.	1.4	3
66	Transferring scientific evidence to oncological practice: a trial on the impact of three different implementation strategies on antiemetic prescriptions. Supportive Care in Cancer, 2004, 12, 446-453.	2.2	34
67	Venous thromboembolism and cancer: new issues for an old topic. Critical Reviews in Oncology/Hematology, 2003, 48, 65-80.	4.4	38
68	Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial. Journal of the National Cancer Institute, 2003, 95, 362-372.	6.3	768
69	Vinorelbine and Carboplatin in Inoperable Non-Small Cell Lung Cancer: A Monoinstitutional Phase II Study. Oncology, 2003, 64, 97-101.	1.9	8
70	Acute effects of pamidronate administration on serum levels of interleukin-6 in advanced solid tumour patients with bone metastases and their possible implications in the immunotherapy of cancer with interleukin-2. European Journal of Cancer, 1997, 33, 304-306.	2.8	17
71	Reversal of Clinical Resistance to LHRH Analogue in Metastatic Prostate Cancer by the Pineal Hormone Melatonin: Efficacy of LHRH Analogue plus Melatonin in Patients Progressing on LHRH Analogue Alone. European Urology, 1997, 31, 178-181.	1.9	47
72	Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. Supportive Care in Cancer, 1997, 5, 314-317.	2.2	29

#	Article	IF	Citations
73	A Randomized Study of Low-Dose Subcutaneous Interleukin-2 Plus Melatonin versus Supportive Care Alone in Metastatic Colorectal Cancer Patients Progressing under 5-Fluorouracil and Folates. Oncology, 1995, 52, 243-245.	1.9	70
74	Prediction of Recurrence in Operable Breast Cancer by Postoperative Changes in Prolactin Secretion. Oncology, 1995, 52, 439-442.	1.9	17
75	A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour. Supportive Care in Cancer, 1995, 3, 194-197.	2.2	26
76	Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. British Journal of Cancer, 1995, 71, 854-856.	6.4	130
77	Efficacy of the Concomitant Administration of the Pineal Hormone Melatonin in Cancer Immunotherapy with Low-Dose IL-2 in Patients with Advanced Solid Tumors Who Had Progressed on IL-2 Alone. Oncology, 1994, 51, 344-347.	1.9	40
78	Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract. British Journal of Cancer, 1993, 67, 1404-1407.	6.4	52